Genomic classifications and radiotherapy for breast cancer.

The current therapeutic strategy in breast cancer rests on standard prognostic factors such as size, histological grade, nodal and hormone receptor status. However, over the last decade, a new form of molecular classification has emerged to complement the classical clinico-pathological staging. Models based on tumour genome have been developped to help predict the risk of relapse, and are currently being evaluated.